Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Other cellular RNAs with partial complementarity to the anti-miR-7 sequence refers to the collection of endogenous transcripts that may inadvertently interact with antisense oligonucleotides (ASOs) or antagomirs designed to inhibit microRNA-7 (miR-7). miR-7 is a critical regulator of various oncogenic pathways, including the EGFR and PI3K/AKT signaling cascades, making it a significant target in oncology research (Horsham et al., 2015, PMID: 25613355). When anti-miR-7 agents are administered, they are intended to bind specifically to the miR-7 sequence; however, the short nature of these sequences allows for potential hybridization with other cellular RNAs that share partial complementarity (Bennett & Swayze, 2010, PMID: 20143915). These off-target interactions can lead to the unintended degradation of messenger RNAs (mRNAs) or the inhibition of their translation, which may result in cellular toxicity or adverse clinical effects (Lindow & Kauppinen, 2012, PMID: 22713471). In the context of drug development, these RNAs represent a major safety hurdle, as they can cause off-target silencing of genes unrelated to the disease pathology (Jackson & Linsley, 2010, PMID: 20844550). Consequently, identifying and minimizing binding to these non-target RNAs is essential for the design of safe and effective miRNA-based therapeutics. This group of RNAs is not a therapeutic target but rather a source of potential side effects and experimental noise in miR-7 inhibition studies.
Unintended hybridization of antisense oligonucleotides to transcripts with partial sequence complementarity, leading to potential degradation or translational inhibition of non-target mRNAs (Bennett & Swayze, 2010).
2 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Other cellular RNAs with partial complementarity to the anti-miR-7 sequence.